Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Asterias Biotherapeutics

Novartis building

Novartis’ Zykadia claims US approval for first-line lung cancer

The Swiss pharma giant’s drug also receives CHMP positive opinion

Novartis building

Novartis’ Zykadia prepped to take on Xalkori in Europe

The Swiss pharma giant’s drug will treat ALK-positive NSCLC patients

AstraZeneca AZ

AZ buoyed by Imfinzi lung cancer trial

Phase III study shows PD-L1 inhibitor increased progression-free survival

- PMLiVE

Merck gains ground in lung cancer with first-line combo approval

Keytruda wins FDA backing for all first-line NSCLC patients

- PMLiVE

Takeda’s gamble on Ariad pays off with Alunbrig approval

ALK-inhibitor will treat NSCLC patients as second-line therapy

- PMLiVE

Unhappy times continue at OncoMed with more disappointing results

Lung cancer candidate tarextumab fails phase II trial

Roche Basel Switzerland

Roche’s Alecensa beats Xalkori as first-line lung cancer therapy

Data shows ALK inhibitor reduces risk of disease worsening

- PMLiVE

Novartis gets lung cancer OK for Tafinlar/Mekinist combo

It can now be used to treat BRAF V600E-positive NSCLC patients in Europe

- PMLiVE

AZ gets rapid approval in China for Tagrisso

Lung cancer treatment becomes first medicine to pass through the country's Priority Review pathway

Bristol-Myers Squibb (BMS) building

BMS replaces R&D head in wake of Opdivo setbacks

As Merck & Co’s Keytruda gains the lion’s share of the market

- PMLiVE

NICE turns down first-line Keytruda for lung cancer

High cost of drug puts it above cost-effectiveness threshold

- PMLiVE

Novartis’ Zykadia nears first-line lung cancer label

Hopes to boost slow second-line sales to compete directly with Pfizer’s Xalkori and Roche’s Alecensa 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links